Navigation Links
Resverlogix Board of Directors Update
Date:9/3/2008

Provides shareholders with an update on strategic review activities

TSX Exchange Symbol: RVX

CALGARY, Sept. 3 /PRNewswire-FirstCall/ - On behalf of Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) the Board of Directors, due to the recent advancement of various discussions with third parties, feel it is prudent to update the market as to activities surrounding a previously announced strategic review process of January 25, 2007. One strategic review option currently under evaluation by the Company is an offer to out-license the Company's NexVas(TM) PR technology for cardiovascular indications to a single Asian country in order to generate non dilutive equity while continuing to further the development of our cardiovascular programs. As a result of the progression of term discussions with more than one Asian pharmaceutical group in this regard, the Board has directed management to proceed with the option for a one country licensing deal concurrently with global deal discussions. To this end, Resverlogix has received a mutually acceptable non-binding proposal for the licensing of NexVas PR and will seek to further advance negotiations. No time frame or terms will be released at this time as there is currently no guarantee that this process will result in a completed licensing deal.

The Board of Directors is also pleased to update shareholders on the ongoing strategic review process pertaining to various types of global partnership deals relating to the NexVas PR technology. Currently, there are three global pharmaceutical companies who are in the process of performing extensive due diligence on NexVas PR and other Resverlogix technologies. Management is also in ongoing discussion with numerous other groups that have shown interest in the NexVas PR technology. The Board is cautious to add that any potential transactions are subject to an extensive negotiation process and there can be no assurance that they will be finalized or tha
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Resverlogix Notice of Conference Call & Webcast
2. Jan Gray Joins Resverlogix Board of Directors
3. Resverlogixs Lead Drug Featured in Key Scientific Publication
4. Industry Leaders Select Resverlogixs RVX-208
5. /C O R R E C T I O N from Source -- Resverlogix Corp./
6. Resverlogix Notice of Conference Call & Webcast
7. Resverlogix Share Option Extension
8. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
9. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
10. Resverlogix is Presenting at IAS HDL Workshop
11. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , September 23, 2014 ... from Imperial Innovations, Cambridge Innovation Capital and Johnson ... clinical cancer genomics company focused on harnessing the ... improve cancer testing and treatment, today announced it ... by Imperial Innovations and including Cambridge Innovation Capital ...
(Date:9/22/2014)... SANTA CLARA, Calif. , Sept. 22, 2014 ... ), the leading source of health information, today released ... that provide novel insights regarding physician and patient perspectives ...  Dr. Eric Topol , a leading authority in ... as both Editor-in-Chief of Medscape and Chief Academic Officer ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
(Date:9/22/2014)... developed a unique nanoscale device that for the ... discovery could have major implications for creating faster ... communication. , The research paper by University of ... Li and his graduate student Huan Li has ... October issue of Nature Nanotechnology . , ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2Engineers show light can play seesaw at the nanoscale 2
... in, GAMMAGARD LIQUID may bind to the ... 15 The University of Tennessee,Health Science Center ... today,announced data from a laboratory study demonstrating natural ... (IGIV),marketed as KIOVIG in the European Union, a ...
... EDMONTON, April 15 /PRNewswire-FirstCall/ - BioMS Medical Corp ... sclerosis (MS), today,announced that Mr. Ryan Giese, Vice President ... Spring Conference., WHEN: ... WHERE: The Princeton Club of New ...
... SAN DIEGO, April 15 SGX Pharmaceuticals, Inc.,(Nasdaq: ... Meeting of the,American Association for Cancer Research (AACR) in ... selective inhibitor of the HGF,receptor tyrosine kinase (MET), inhibits ... presented in the afternoon poster session,entitled Small Molecule Kinase ...
Cached Biology Technology:Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 2Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 3Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 4Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease 5BioMS Medical to present at EQUITIES Conference 2SGX Presents Preclinical MET Data at AACR 2SGX Presents Preclinical MET Data at AACR 3
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... 22, 2014) As genetic sequencing technologies continue to ... a critical need to establish appropriate policies and regulatory ... have said. A special policy issue of the ... today and edited by experts with the Center for ... Medicine gives policy makers the tools to jumpstart this ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... 2009)The University of Texas at San Antonio (UTSA) has ... Science Foundation (NSF) to study nanomaterials and their biomedical ... Research and Education in Materials grant, is the second ... Recently, UTSA announced the receipt of $5 million to ...
... risk for type 2 diabetes, not only do waistlines matter to ... This new discovery by a team of Swedish researchers was just ... explain why some women of normal weight develop type 2 diabetes, ... the link between enlarged fat cells and the development of type ...
... of the most intriguing developments in recent medical science is ... detection in 1988, over 22,000 scholarly articles (about 3 per ... of drugs has been developed, and 25 Phase I, II ... and medical communities involved in ET move towards 25 years ...
Cached Biology News:UTSA Physics Department receives $2.7 million to study nanomaterials 2Size of fat cells and waist size predict type 2 diabetes in women 2International conference on endothelin 2International conference on endothelin 3
... Double staining is a technique used to ... tissue.(1-6) PicTure™-Double Staining Kit is a Zymed ... two antigens simultaneously in the same human ... The antigens can be identified using two ...
... Identical to the D-2000, but comes with ... switch) The D-2000 Deuterium Light ... nm. In addition, deep-UV versions of the light ... 190-400 nm. This powerful and stable lamp provides ...
... assay kit designed to detect poly(ADP-ribose) polymerase ... an enzyme implicated in DNA damage and ... by caspase-3. Cleavage of PARP from the ... a hallmark of apoptosis. Each kit is ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
Biology Products: